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It is always attractive and seductive to describe any time in
research as being one of transition, where the knowledge and
insights of past work and the tools of our trade coalesce to fun-
damentally alter our concepts, our approaches, and our capaci-
ty to make progress. In truth, it is often easy to argue the case
for such a transition, or even a transformation, but it is exceed-
ingly difficult to prove.Whether we are at a profound transition in
cancer research is an interesting question. The answer may be
yes, but it may be more of a reflection of a long and ongoing
transition rather than a unique inflection point. That said, I
believe that we are at a point of emerging synthesis, new direc-
tions, and the emerging possibility that the science of cancer
research could actually inform and transform the approach to
cancer in patients and in populations. I am taking the liberty of a
perspective to take a more conceptual overview of the types of
questions being asked, to discuss how the enormous amount of
knowledge gained over the past decades can be organized, and
to point to the challenges (conceptual and technical) that lie
ahead. I focus on the process of organization and synthesis
because it is our emerging ability to bring a higher level of order
to how we think about cancer, pulling together the flood of infor-
mation garnered by thousands of researchers over decades,
that, in part, provides a useful description of the beginning of
the twenty-first century as a transition period in cancer
research.
There is a bit of a paradox here. On the one hand, our
emerging ability to synthesize information and to bring some
simplifying order to cancer defines one aspect of this transition
time, while on the other hand, as I will discuss, it is the need for
and ability to begin to address cancer more directly in terms of
its complexity that will characterize cancer research as we
move forward. In the first, we are bringing together immense
amounts of information gathered through a very successful
reductionist approach to the study of cancer cells. In the sec-
ond, we will need to address the study of cancer as very com-
plex systems whose machinery needs to be understood in mul-
tiple specific contexts—of interacting molecular networks, of the
cellular lineages involved, and of the individual in whom the
cancer has developed. With the first, we are attempting to
answer the question, “What is the molecular nature of cancer?”
With the second, we are attempting to answer surprisingly sub-
tle and complicated questions, such as “How many different
cancers are there?” and “How do the molecular components of
cancer play out in causing a specific disease in a particular indi-
vidual?”
The nature of cancerA satisfying synthesis
The long and frustrating history of cancer research over the first
seven decades of the twentieth century seemed to provide little
in the way of unifying concepts. Attempting to connect models
for the nature of cancer with insights gained from the study of
the causes of the disease proved confusing. Causes ranged
from radiation to chemicals to infectious agents to heredity. It
was the growing recognition that DNA was the crucible through
which the external and internal environments, experience and
heredity, came together that provided our first great unifying
view (Bishop and Weinberg, 1996).We now know that cancer is
an acquired genetic disease in which a single clone of cells and
its progeny accumulate heritable changes that result in the cel-
lular phenotype of cancer. This realization set the stage for the
modern era of cancer biology. Our goals have been clear: (1) to
define the mechanisms by which cells acquire and fix genetic
changes, (2) to identify the specific changes, (3) to understand
the functions and malfunctions of the genes involved, and (4) to
elucidate the roles of specific changes in either the develop-
ment of and/or the behavior of cancer cells.
The genetic nature of cancer has now been amply demon-
strated—first, by the remarkable and productive application of
human genetics to cancer; second, by the successful produc-
tion of cancer in mice via the specific engineering of alterations
in the orthologous genes to those identified in humans; and
third, by the validation of the critical role of defined pathogenet-
ic changes in human cancer by the development of drugs that
work by targeting such genetically defined cancer-specific
altered molecular machines. The best example of this is the
recent experience with an inhibitor of the abl kinase in CML
(Mauro et al., 2001). This work capped a long (4 decades) story
that first identified the Philadelphia chromosome as a character-
istic heritable change in the structure of the genome in CML
cells. The nature and function of the product of this genomic
change was identified as the bcr-abl fusion, which constitutively
activates the abl tyrosine kinase, and the activity of this kinase
was shown to be essential for the proliferation and survival of
the leukemic cells. Next, the introduction of the fusion gene into
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the mouse produced a CML-like leukemia. Finally, the use of an
active inhibitor of the abl kinase in patients induced remission in
the chronic phase of the disease. The failure to sustain remis-
sions in the accelerated or blast phase is associated with spe-
cific molecular mechanisms of resistance to the ability of the
drug to inhibit the kinase (Hochhaus et al., 2001; also see
Druker, 2002 [this issue]).
A further typology of the nature of cancer
I think it unlikely that we will replace our current view of the
nature of cancer as a disease of heritable changes in a single
clone of cells. However, we can refine the question of the nature
of cancer into a more structured typology, through which we can
answer the question of the nature of cancer along three lines.
For each of these, I will present a description of a simplifying
commonality across cancers, but also address the great chal-
lenges that these common themes face in light of both the com-
plexity of cancer and of the recognition that the manifestation of
cancer (i.e., the actual development and behavior of the dis-
ease) will likely only be fully apprehended when we can address
the context in which the molecular changes and the disease
take place. This threefold description of the nature of cancer
most fully describes the vast majority of solid tumors seen in
adults (which represents the vast majority of cancer).
Accordingly, cancer can be seen as:
(1) A disease of genomic instability.
(2) A disease of altered cellular behavior.
(3) A disease of altered tissue behavior.
The first provides the underlying basis for the development
of cancer. The second provides the most traditional view of the
requisite acquired characteristics of the cancer cell. The third
recognizes that a tumor is not just a collection of cancer cells,
but is rather a complex organ or set of organs (primary tumor,
metastases) whose properties reflect the interactions between
genetically altered cancer cells and the host.
One caveat before exploring this typology: any attempt to
organize a description of the nature of cancer should allow us to
better think about and to more effectively talk to each other
about cancer. One would hope that this organization frames
both the types of research questions we ask and meaningfully
differentiates the underlying mechanisms.While the former is a
matter of convention and utility, the latter is a real and important
challenge. The search to understand the nature of cancer leads
us to the current consensus of cancer as a complex somatic
genetic disease. Any mechanistic typology of cancer should
organize a division of characteristics or features about cancer
that correlate with the genetic changes that are responsible for
those characteristics. The problem is that the more we explore
the critical genes and pathways in cancer, the less neatly they
seem to sort between the disparate features of nearly any can-
cer typology.We can think about this as the “one gene-one phe-
notype” problem of cancer. Cancer emerges as a process
whereby new phenotypes become manifest over time. The
emergence of these new phenotypes must reflect the accumu-
lated effects of fixed and heritable genomic changes. Yet, the
more we look at the function of genes whose activities are
altered in this process, the less neatly those functions divide
into current descriptions of the distinct characteristics of cancer.
Thus, genes associated with control of proliferation of the can-
cer cell may also be involved in genomic instability or vascular-
ization of tumors. Genes involved in invasion may also be
involved in growth control or apoptosis.
One simple explanation for this is that we are not accurately
describing phenotype, differentiating between characteristics
that are actually distinct manifestations of a single cellular phe-
nomenon. Alternatively, there may be some fundamental princi-
ples at work, whereby the distinct attributes of cancer involve
molecular pathways that must interact with each other. Despite
this complexity, the central challenge of cancer cell biology is to
identify the genes whose changes are associated with cancer
and to then identify how the changes in those specific genes
and gene products are connected to the behavior of the cancer.
The simple possibility of cataloging genetic changes and phe-
notypic changes and then matching them to each other will be
hard to achieve. The genotype-phenotype challenge in cancer
will more likely require that we address issues such as:
(1) What is the meaning of the particular combination of
genetic changes seen in cancer, and how do these changes
interact with each other?
(2) Is the order of acquisition of genetic changes important?
(3) How many genetic changes actually contribute to the
cancer phenotype?
(4) How does the content of the specific cell lineage affect
the pathways and phenotypes of cancer?
(5) How do host factors modify the genotype-phenotype
relationships?
Despite the complexity underlying our attempt to correlate
cancer genotype with phenotype, great progress is being made
in both identifying and characterizing critical “cancer genes”
(Hahn et al., 1999). Furthermore, conceptual relationships are
emerging that may explain the patterns of genetic changes
seen and not seen in cancers. In general, a limited number of
pathways, such as Rb and p53, are altered in the vast majority
of tumors. A single pathway (i.e., Rb) is altered at only one com-
ponent of the pathway in each tumor. There are strong and
unexplained biases in which pathways and/or the components
of a common pathway are altered in particular tumors or tumor
types. Finally, tumor development involves phenotypes that
drive a cancer cell to acquire a new type of behavior or state,
and those that allow the cancer cell to tolerate either the altered
state or its consequences.
Therefore, one can view critical genetic events in the devel-
opment of cancer as series of paired changes. This is not to
imply a mechanistic or temporal coupling, but rather the need
for a second event to allow the survival of cells altered by a first
event. For example, the massive genomic instability associated
with the majority of carcinomas (see below) would be expected
to result in the activation of checkpoint and protection systems
that would lead to cell cycle arrest and/or apoptosis. To become
a tumor, a second site (this may actually be multiple “second”
sites) must be altered to allow the cell to either ignore the
genomic structural abnormalities or to uncouple its recognition
from either arrest or apoptosis (for example, by the induction of
the p53 pathway). Similarly, there have been reports of alter-
ations in components of a likely mitotic checkpoint (Bub1 and
hsMAD1), which might allow cells to survive the anaphase
bridges and premature onset of anaphase, that may underlie
some aspect of genomic instability in cancer.
Cancer as a disease of genomic instability
It is well documented that cancer is the result of the accumula-
tion of heritable genetic changes in a single clone of cells and its
progeny, endowing that clone with the variety of properties we
ascribe to cancer. It has been more difficult to demonstrate the
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more fundamental question of whether these genetic changes
are themselves a manifestation of true genetic instability. The
question of whether cancer, which clearly reflects the results of
accumulated genetic changes, is a manifestation of an
increased rate of production of such changes or rather the clon-
al expansion and selection of cells having undergone a normal
rate of mutation has long been debated. This question has
recently been nicely reviewed (Lengauer et al., 1998). However,
recent genetic and biochemical evidence strongly supports the
notion that genetic instability may be a defining molecular
descriptor for most cancers.
There are two types of generally nonoverlapping genetic
changes seen in most cancers: subtle sequence alterations and
gross changes at the chromosomal and subchromosomal level.
The latter are much more common, seen in over 80% of carci-
nomas, but it is the former that has given us the clearest answer
to the critical role of genetic instability in the development of
cancer. This is because of the precise identification of inherited
genetic changes in well characterized genes involved in either
Nucleotide Excision Repair (NER) or Mismatch Repair (MMR)
that give rise to cancer. The changes seen in these cancers
involve deletions or insertions of small numbers of nucleotides
and base substitutions. In most other cancers, the genomic
instability is manifested by gross changes observable at the
karyotypic level, and include whole chromosome number
changes, or, more commonly, sequential losses or duplications,
chromosomal translocations, and amplifications and/or dele-
tions of smaller (5–10 Mbase) regions of chromosomes. For all
of these manifestations of either subtle or gross instability,
assays have now demonstrated that the rate at which the can-
cer cell accumulates these changes is greatly elevated over that
seen in similarly growing cells that lack the particular instability
phenotype. It is worth pointing out that the exceptions to this
general description of cancer as a “disease of genetic instabil-
ity” are the cancers, generally noncarcinomas, that possess sin-
gle, reproducible balanced translocations of specific chromoso-
mal sites (i.e., leukemias, some lymphomas, Ewing’s sarcoma).
In these cases, there is no evidence of any underlying state of
genomic instability.
As highlighted above, genomic instability is associated with
either subtle changes (so-called MIN and NIN) or with gross
changes (so-called CIN). The most satisfying explanation for
this is that a tumor needs to activate one genetic pathway to
genetic instability. Such an “either/or” argument actually sup-
ports the notion that tumors must “find” one pathway to genetic
instability, but once one is acquired, there is no selective advan-
tage to acquire another. While satisfying, we have not formally
ruled out the possibility that the simultaneous expression of
both MIN and CIN might be selected against (although there is
neither evidence nor mechanism for this).
Many questions remain to be answered about genomic
instability and cancer. A discussion of three important areas that
we need to better understand, including the mechanism of
gross instability, the patterns of chromosomal changes in can-
cer, and allele-specific genomic changes, follows.
Mechanism of gross instability
While the mechanisms underlying MIN (and NIN) are relatively
well understood, the mechanisms underlying CIN are not only
not understood, they have yet to be cataloged. It is very possible
that a large number of totally distinct mechanisms will prove to
be responsible, and whether they act by gain-of-function or
loss-of-function is unclear. Possibilities include the multitude of
genes involved in double-strand breakpoint repair, the many
steps involved in appropriate alignment, condensation, cohe-
sion and separation of sister chromatids, centrosome number,
and function control, and an increasing number of checkpoint
processes that monitor mitotic events. Cancer-associated
genes that have been associated with the DNA-damage check-
point whose loss may be associated with chromosomal segre-
gation abnormalities include ATM, p53, and BRCA1 and 2.
Genes associated with abnormal control of centrosomal num-
ber and function include p53 and the aurora 2 kinase. Genes
associated with a potential spindle checkpoint include BUBl and
hMAD2.
Recently, a series of observations, first in the mouse (Chin
et al., 1999) and, more recently, in human cancers (Gisselsson
et al., 2001), point to an interesting role of shortened telomeres
in the generation of many of the genomic features of CIN.
Shortened or absent telomeres can lead to the fusion of chro-
mosomes and the formation of dicentric structures. These can
form bridges at cell division that are resolved either by fragmen-
tation and/or unequal distribution to daughter cells. The frag-
mented chromosomes may again fuse and repeat the cycle of
breakage-fusion-bridge formation first described by McClintock
in 1941. Many aspects of the unstable karyotype of human can-
cers can be explained via this mechanism (coupled with the
capacity, perhaps via loss of p53, to survive these changes).
Thus, it may be that the proliferation of cells and the subsequent
shortening of telomeres seen in human carcinomas is a critical
step in the generation of genomic instability that, in turn, drives
the evolution of cancer. While an attractive notion, many ques-
tions remain as to the details of such a model. The dependence
of this model on telomere length has several implications. It has
been proposed as the explanation of why p53+/− mice do not
develop common epithelial tumors until they are crossed to a
telomerase null background. Mice have much longer telomeres
than humans, and the genetically induced shortening of murine
telomeres thus “humanizes” the tumor phenotype of the p53+/−
mice.
Patterns of chromosomal changes in cancer
If we are to correlate the genomic changes in cancer with mean-
ingful functional changes, we will need to identify, catalog, and
interpret those changes. Clear progress has been made in this
regard, but it is largely limited, for obvious reasons, to the sin-
gle, reproducible translocations seen in leukemias, certain lym-
phomas, and the exceptional nonepithelial solid tumors, partic-
ularly those of childhood. We are only now beginning to mea-
sure and catalog the changes seen in common human tumors.
Which changes are recurrent? Which affect important gene
function? How do the observed changes reflect the underlying
mechanism of genomic instability? Do the changes only reflect
the underlying mechanism, or do they also reflect the selection
of changes that confer tumor growth advantage? Other impor-
tant questions concern the relationship between genomic/
genetic changes and tumor development. A large amount of
data supports the idea that in tumors with gross genomic insta-
bility, the extent of genomic change increases with the temporal
development of the tumor. On the other hand, recent data
demonstrate that a large amount of gross genomic changes
occur early, detectable even in lesions such as DCIS of the
breast (Snijders et al., 2001). A recent study of pancreatic can-
cer (an epithelial tumor) and osteosarcoma (a mesenchymal
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tumor) suggests a possible temporal pattern of first telomeric
and then interstitial and centromeric breaks as a manifestation
of repetitive breakage-fusion-bridge cycles initiated by telomer-
ic shortening.
Allele-specific genomic changesWhere molecular genet-
ics may meet molecular epidemiology
One area of the molecular genetics of genomic instability ripe
for exploration is the allelic patterns of the observed chromoso-
mal changes.Tumors may lose or alter up to 50% of their alleles.
This is characterized by the common loss of heterozygosity of
many loci which is often accompanied by a gain of function of
the remaining allele. This gain may result in a normal karyotype
of the region but an abnormal allelotype.Often a particular allele
is duplicated.Too little is yet known about allele-specific amplifi-
cations in cancer.We are at a propitious time now (with the com-
pletion of the genome, the identification of large numbers of sin-
gle nucleotide polymorphisms, and high throughput analysis of
tumor samples) to ask whether or not amplifications are random
with respect to common human polymorphisms. If tumors select
for specific alleles to be lost, retained, gained or amplified, we
may be able to identify polymorphisms that either predispose
(perhaps weakly) to cancer in the general population or modify
the evolution and/or behavior of tumors once begun.
Cancer as a cellular disease of altered circuitry and altered
cellular behavior
This is the definition of cancer that has been the most intensive-
ly and productively studied over the past several decades. An
excellent perspective on this topic was published two years ago
in Cell by Hanahan and Weinberg (2000), appropriately titled
“The Hallmarks of Cancer.” They described six acquired capa-
bilities that define the malignant state, four of which I will include
in this cellular aspect of the nature of cancer: relative self-suffi-
ciency in growth signals, insensitivity to antigrowth signals, eva-
sion of apoptosis, and limitless replicative potential. The chal-
lenge that remains, as those authors pointed out, is to cope with
both the complexity and the contextual issues that connect what
appears to be a limited number of phenotypes and basic molec-
ular circuits with the nature and evolution of each type of human
cancer.
Issues of complexity and context come in several flavors.
One is the question of the definition of each cancer, and anoth-
er is how many different cancers there are. Cancers have been
traditionally classified by their histogenic origin. This has been
refined as the presumed cell of origin has been discerned, first
anatomically, then microscopically, and more recently, by the
added use of molecular markers. Over the past several
decades, we have begun to add molecular markers that are
more closely associated with the circuitry and even the molecu-
lar pathogenesis of the cancer. These include specific translo-
cations, amplifications, and mutations in molecules relevant to
both cell behavior and therapy, such as the estrogen receptor. A
recent explosion of comprehensive molecular analyses of can-
cer, primarily using transcript expression arrays, is revealing
new molecular heterogeneity within histogenic classes of can-
cer (Alizadeh et al., 2000; Perou et al., 2000; Ramaswamy et al.,
2001). Despite a rapidly growing literature, it is too early to know
what exact picture of tumor heterogeneity will emerge from this
approach. Several tentative conclusions from these studies are:
(1) that there is considerable heterogeneity of gene expression
both between tumor types and, in some cases, within currently
classified tumor types; (2) that metastatic lesions appear similar
in overall gene expression to their primary tumors; and (3) that
heterogeneity may represent some combination of cell of origin,
pathogenetic pathways, and sample heterogeneity. Challenges
to extracting optimum information from array analysis will
include sample preparation, standardized methodologies, fuller
and richer annotation of the human transcriptome, and larger
collections of data correlated with relevant clinical descriptors.
Another obvious challenge of complexity will emerge as
more experimental data fleshes out the circuits and signaling
pathways. It is already clear that these pathways themselves
are complex, branched, and overlapping. They are, in many
cases, beginning to look more like networks that intersect and
“crosstalk,” rather than simple linear and distinct pathways
(Hunter, 1997).While the pathways and networks that we draw
define demonstrated connections, it may well be important to
refine, annotate, and understand the connectivity maps in terms
of the quantitative, temporal, and spatial details of the connec-
tions. If we are to understand the flow of information through
these networks and how this is perturbed by changes in the pro-
teins involved, we will need new experimental approaches that
will add kinetic and other quantitative measures. This will not
only be a future experimental challenge, it may also require
rethinking the reliability of some of the pathways as we current-
ly perceive them, particularly if the underlying data has relied
too heavily on protein overexpression studies. In short, we need
to move from a description of cellular circuits as reflecting the
possible or potential biochemical connections to a description of
the physiological and pathophysiologically relevant connec-
tions.
Raising the question of relevance moves us from the chal-
lenge of complexity to the challenge of contingency or context.
We can consider three types of contingencies within which we
need to understand cancer pathways:
(1) How pathways function in the context of the acquired
genetic changes in a tumor.
(2) The functioning of pathways in different cell lineages.
(3) The effects of the individual’s genetic background.
The pathways implicated in cancer are highly interconnect-
ed, but we have little systematic information about cancer cells
that allow us to conclude whether or not there are specific or
preferred combinations of alterations in cancer cells. It will be
interesting and informative to develop a comprehensive data-
base of the multiple altered pathways present in any given
tumor to look for such combinatoric genetic changes.This ques-
tion of which specific alterations tend to occur together in any
specific cancer likely intersects with the second contingency
issue—that of the effect of the cell of origin of the cancer. An
enormous amount of data makes it abundantly clear that differ-
ent cancers (defined histogenically and by site of origin) display
different frequencies of specific genetic changes. For example,
APC is lost in the majority of colorectal cancer but rarely in other
cancer types, while VHL loss is largely limited to renal cell carci-
noma and ras is commonly mutated in pancreatic cancer but
rarely in a variety of other tumors.Why is this? We are beginning
to understand that the lineage of a cell seems to have a pro-
found effect on how any pathway and/or any component of a
pathway is either wired or interpreted. Accordingly, the conse-
quences of changing specific components and specific path-
ways may be profoundly different in different lineages. These
differences may be attributed to the inability of a specific cell
type to survive, to compensate, or to “care” about changes in
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any given pathway or component.
One recent study illustrates the type of lineage contingen-
cies that exist and that will explain the molecular peculiarities of
specific cancers (Yu et al., 2001). Cycin D1 is overexpressed in
up to 50% of human breast cancer. In these tumors, this overex-
pression is most likely the mechanism by which the Rb pathway
is inactivated. When cyclin D1 is homozygously deleted, mice
fail to develop mammary tumors when either ras or neu is over-
expressed in mammary epithelium. In contrast, mice that over-
express either Wnt1 or myc continue to develop breast tumors
in the absence of cyclin D1, Thus, ras and neu, but not these
other two oncogenes, must communicate with the Rb cell cycle
regulator through cyclin D1. Strikingly, these cyclin D1 deficient
mice continue to develop other tumors driven by either ras or
neu. In fact, these authors showed that in cyclin D1 null fibro-
blasts, transformation by ras or neu resulted in elevation of
cyclin D2 and cyclin D3, something that mammary epithelial
cells could not do. Thus, as the authors point out, the ways
these ubiquitous biochemical pathways are wired are different
in the various cell lineages.
One of the great challenges in cancer biology, indeed in all
human biology, is to understand how distinct genetic variations
among individuals effect the manifestation of disease, from
environmental exposures to the penetrance and expressivity of
either inherited or, in the case of cancer, acquired genetic states
(Figure 1). The way that polymorphisms, especially common
population polymorphisms, influence the development and
manifestations of cancer and even the response to therapy is a
challenge that we have barely begun to address. There is every
reason to believe that genetic interactions will be an illuminating
and important aspect of understanding cancer. Our strongest
clues supporting this last statement come from the documenta-
tion of clear differences in the expressivity and penetrance of
inherited cancer syndromes in humans and from observations
about cancer in the mouse. Individuals who inherit mutations in
strong cancer susceptibility genes have widely varying probabil-
ities of developing cancer. Some of this may be due to the pen-
etrance of specific mutations, some may be due to environmen-
tal and exposure effects, some may reflect stochastic events,
and some reflect a rich and powerful effect of the individual’s
genetic background. Such effects have been abundantly
demonstrated in the mouse, where strain-specific effects of
expressivity and penetrance are dramatic (Balmain and
Nagase, 1998). The effects of these so-called modifier loci can
be on almost any aspect of cancer development from initiation
to progression (Balmain, 2002).The identification of the specific
genes that modify cancer incidence and/or behavior is in its
infancy. This process has been hampered by the expense and
time that the experiments require, the absence of the complete
mouse genome sequence, and the fact that strain-specific
effects often reflect the contribution and interaction of multiple
polymorphic loci. Despite these difficulties, I believe that the
identification of mouse modifier genes, coupled with the devel-
opment of mouse models of human cancer, will prove to be
immensely illuminating.They will provide insight into how critical
biochemical pathways interact with the cancer cell circuitry.
These modifier pathways may themselves be altered in cancer
cells, or may determine how the host interprets and/or responds
to primary circuit alterations in cancer. The first and best
described murine cancer modifier (Cormier et al., 2000),
MOM1, was identified as a strain-dependant variant(s) that
modified the expression of intestinal tumors in mice with
germline mutations of the APC gene. Interestingly, the gene
responsible for at least half of the modifier effect, a secretory
phospholipase, is not expressed in the tumor cells, but rather in
the normal intestinal crypt cells of the host. The implications of
this finding lead us to the third aspect of this tripartite typology
of cancer.
Cancer as a disease of dysregulated tissue behavior
Perhaps the greatest challenge facing the cancer biologist
will be to move from the discovery, description, and elucidation
Figure 1. The complex process of carinogenesis
Cancer arises through the accumulation of genet-
ic alterations within a subset of our genes.  Certain
of these genetic alterations can be hereditary
whereas others alterations arise as a result of expo-
sure to carcinogens and certain oncogenic virus-
es.  It is clear that commonality in exposure does
not lead to common outcomes in terms of cancer
development.  Modulators of carcinogenesis inc-
lude hormones, diet, and a range of other host
factors.  The impact of exposure to carcinogens as
well as the influence of these modulators are in a
sense "filtered" by an individual's genes that can
eliminate, reduce, or enlarge the impact of a
given contributor to the process.  In the figure, this
modulation by the individual's genes is represent-
ed as elimination, reduction, or enlargement of
the arrows as they pass through the genetic "filter".
Understanding the process of carcinogenesis will
require a much more comprehensive understand-
ing of gene-environment interactions than exists
today.
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of the components and pathways within the cancer cell to study-
ing cancer as the manifestation of a set of complex interactions
between the cancer cells and the cells and tissues of the host.
This is the least understood area of cancer biology and, from
the viewpoint of the patient, the most important. It is in this realm
that we must learn to understand how cancer cells subvert the
architecture of the tissue in which they develop, create a patho-
logic organ (called a tumor), spread, and metastasize. While
this aspect of cancer biology has largely been focused on the
processes of invasion and metastases, it is clear that there are
few phenotypes of the cancer cell that do not involve a complex
and intimate set of interactions between the cancer cell and the
host. Even at the earliest stages of cancer development, the
development of dysregulated growth and survival requires an
altered set of interactions between the cancer cells and neigh-
boring cells. This may include altered production of paracrine
growth control signals (both positive and negative) and altered
physical interactions between cancer cells and noncancer cells,
as well as between cancer cells and the extracellular matrix
(Aplin et al., 1998). Some of the most common alterations in
cancer involve changes in the expression of E-cadherin, a cell-
cell interaction molecule found on all epithelial cells. Altered pat-
terns of expression of the complex integrin family of proteins are
common, resulting in changes that have yet to be deciphered in
cancer cell-ECM interactions. These sorts of changes presum-
ably underly many of the aspects of the ability of the cancer cell
to grow and survive within the structured confines of a tissue,
and are also part of the fact that tumors are not just collections
of proliferating cancer cells, as generally studied in the labora-
tory, but rather are highly reprogrammed tissues made up of
cancer cells and conscripted host cells, many of which may be
altered by signals from the cancer cells and whose signals may
be essential to the cancer cells.
To grow, spread, and metastasize requires that cancer cells
achieve a number of goals:
(1) They need to alter the growth inhibitory signals that are
normally received from surrounding cells and stroma, either by
changing the signals or how they are deciphered by the cancer
cells.
(2) They need to lose the normally tight cell-cell and cell-
stroma physical interactions via adhesion molecules.
(3) They need to be able to remodel the local architecture,
largely through altering the expression and activity of extracellu-
lar proteases.
(4) They need to recruit, create, and remodel vasculature
(Folkman, 1997).This involves both angiogenesis and lymphan-
giogenesis (Stacker et al., 2001).
(5) They need to acquire the capabilities of invasion and
migration, and spread through tissues and out of the tumor via
blood, lymph, or tumor-derived vasculature.
(6) They need to be able to establish new ectopic tumor-tis-
sue structures via the process of metastasis.
There is an emerging body of work adding to this complexi-
ty, whereby signals arising in a tumor may reprogram both “nor-
mal” and cancer cells. In the former case, normal fibroblasts
may be “rewired,” coevolving with the cancer cells to support in
some essential ways the growth, evolution, and development of
the cancer cells (Olumi et al., 1999; Skobe and Fusenig, 1998).
The merging sense in both cancer biology and biology in gener-
al of the extraordinary plasticity of cells will become an impor-
tant aspect of understanding the complex tissue biology of a
tumor. An intriguing example of this plasticity is the observations
that cancer cells may take on the structure and function of vas-
cular cells in a process called vascular mimicry (Hendrix et al.,
2001).
In addition, the same one genotype-one phenotype prob-
lems discussed earlier in assigning functions to altered cancer
cell circuitry arises in attempting to explain the heterotypic biol-
ogy of tumors. It is problematic and likely wrong to assign a sin-
gle functional role to a gene product or molecular pathway in a
specific cell or tissue phenotype. For example, extracellular pro-
teases, long studied in cancer to explain cancer cell invasion
(Werb, 1997), are now recognized to effect angiogenesis
(Stetler-Stevenson, 1999) and the control of growth of the can-
cer cell. Adhesion molecules and their modulation affect cell
growth (Aplin et al., 1998), apoptosis, invasion, and metastasis
(Johnson, 1991).
Our “parts list” of the complete set of cellular players in any
given tumor remains incomplete.We not only will need an enu-
meration of the cell types engaged in a given tumor, but also a
molecular description of the components that define the multi-
ple and reciprocal interactions among all of these cell types.
Finally, metastasis is a particularly critical aspect of tumor
cell biology, as it is this process that explains the lethality of can-
cer. Progress is being made in many aspects of this problem.
We are beginning to identify, in certain tumors, what patterns of
gene expression correlate with metastatic potential (Clark et al.,
2000; Saha et al., 2001). To understand metastasis, we need to
explain the multiple ways by which cancer cells leave their site
of origin, find their preferred site of ectopic residence, and
recreate the tumor tissue at this new site.The ways in which the
striking biases of particular organs of metastasis for specific
cancers are determined has been the subject of much research
and model building. Evidence now supports multiple models
Figure 2. The multiple strands of cancer research 
A, B, and C represent different cancers that are
each characterized by: (1)distinctly altered com-
ponents; (2) distinct alteration of cell circuitries; (3)
distinctly altered intracellular signaling networks; (4)
the meaning of the altered circuitry is dependent
upon the cell lineage and the history of the devel-
oping cancer; and  (5) the final tumor that results is
due to the interactions of the cancer cells in the
context the host. In ways that are yet to be eluci-
dated (question marks), all of these phenomena
weave together to produce a particular cancer.
1. Components
of cells differ
2. Circuitries
of cells differ
3. Complexities
of cells differ
4. Contingencies
of cells differ
5. Contexts
of cells differ
Malignant
Tumor
A
B
C      
?
?
?
CANCER CELL : FEBRUARY 2002 9
C O M M E N T A R Y
(Liotta, 2001), including matching appropriate growth and
growth control factors between the cancer cells and the target
organs, the expression of specific adhesion factors that recog-
nize organ-specific molecules found in the vasculature, stro-
ma, or other organ components, and homing mechanisms.
The identification of chemokine receptors on specific cancer
cells coupled with the organ-specific production of specific
chemokines offers a new basis for the role of chemoattractant
homing in metastasis (Muller et al., 2001).
Toward a synthesis in cancer biology
While the molecular and cellular components of cancer will
continue to be elucidated, the future of cancer biology research
will move from a productive reductionism toward a more syn-
thetic approach. This new approach will not ignore reductionist
inquiry but will rather incorporate and better annotate the find-
ings gleaned from taking tumors and cancer cells apart. This
synthesis of inquiry and approach will require that we consider
cancer at various levels and integrate the findings at one level
within the context of another (Figure 2). While we continue to
identify the components whose functions are central to the
behavior of the cancer cell, we will need to characterize these
as functioning in a limited number of circuits. These circuits will
be more clearly described as highly complex and interacting
networks, which in order to be understood will require detailed
and quantitative descriptions of how they operate, both tempo-
rally and spatially. Next, we will need to document and explain
the particularities of what I have referred to as contingencies.
This refers to how the cell decodes and responds to alterations
in components, circuits, and complex networks as a function of
cell lineage, state of differentiation, and the unique molecular
history of each cancer. Finally, in order to actually understand
the development and behavior of cancer, we will need to under-
stand the context in which the cancer cell develops and sur-
vives. This last issue represents, not surprisingly, our greatest
challenge, but one that will reveal both the greatest surprises
about cancer and the major conceptual breakthroughs of the
next decade.The additional challenge of context will involve the
elucidation of how multiple allelic variations determine or influ-
ence cancer pathogenesis, behavior, and response to interven-
tion within the human population and in any given individual. So,
approaches used to gather information at each level will need to
be addressed in the context of each of the other levels.Thus, we
will need to describe the components, circuits, and complex
networks for each relevant contingency and in each cell type of
a tumor, as well as the higher order interactions that create new
contingencies, etc. This description of the challenge of cancer
biology is analogous to the challenge of developmental biology.
Indeed, it is not a coincidence that the critical components,
pathways, and many of the principles of development are used
in and are central to cancer. If we accept the proposed typology
of cancer presented here—that it is a disease of dysregulated
tissue behavior which, in turn, is a manifestation of the geneti-
cally altered behavior of a clonally proliferating and immortal
population of cancer cells, which itself is the result of a funda-
mental disorder of genetic/genomic stability in that clone—then
the ultimate synthetic understanding of cancer is very much a
problem of a pathologic developmental process.
The use of model systems derived from many species, but
most particularly the mouse, needs to be pursued. We will
require the further development and maturation of high through-
put analysis of genomic, genetic, and epigenetic changes, gene
expression, and protein profiles, as well as the corresponding
development of new approaches to sample preparation and the
ability to assign molecular changes to single cells. The study of
complex tumors and imaging techniques that will allow us to
study tumor development, growth, spread, and metastases in
real time (and that provide structural, anatomic, functional, and
molecular information) needs to be developed further.The iden-
tification of contributing genetic factors will be achieved by new
approaches to the rapid detection of human variation and total
genome scan methods, as well as candidate locus and gene
examination. In addition, this effort will likely require the use of
data derived from mouse genetics and from the examination of
recurrent genetic changes and allele-specific gains and losses
in the tumor itself. New analytic tools and extensive use of math-
ematical modeling will be essential if we are going to make
sense of the flood and complexity of the data that will be gener-
ated by this synthetic approach. The amount of information, the
variety of observations, and the combinatoric possibilities indi-
cate that we will need to enhance the acquisition of data and
work toward the assembly of new cancer biology databases that
will allow us to search for and test the patterns that will yield the
synthetic pictures of cancer that we are seeking.
There is little question that the molecular elucidation of can-
cer is fundamentally changing the way we think about the pre-
vention, detection, diagnosis, and treatment of cancer.
Some few recent clinical advances with both targeted
monoclonal antibodies and specific small molecule inhibitors
have revealed the potential of translating molecular knowledge
to clinical practice, despite all of the remaining unknowns about
cancer biology. One can certainly question how much we need
to know and understand before we can develop better interven-
tions.The answer is twofold. First, we should and will act oppor-
tunistically to attempt to apply what we are learning as that
knowledge accumulates. Second, there simply is no definitive
answer to the question. My own belief is that we are only at the
very beginning of a rational, molecular, and predictable
approach to cancer intervention. These new molecular thera-
pies are valuable and exciting. They demonstrate a proof of
principle and provide a glimpse into the future. However, the
task before us remains daunting.We continue to have very few
effective and specific ways to treat the vast majority of common
tumors once local therapy is not an option. I hope that this per-
spective indeed describes that we are at a transition point in
cancer biology, one that builds on all of the progress of the last
several decades. This is not because we are on the verge of
rapidly curing cancer, but rather because we are on the verge of
being able to move into a new era of basic cancer research that
will begin to weave the disparate and multiple threads of cancer
biology together, addressing the enormous complexity of
human cancer and preparing us to really apply what we learn to
transform the way we intervene to prevent and cure the many
diseases we call cancer.
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